NBN. V. Bronina

N. V. Bronina

*This is an algorithmically generated author record based on publicly available information.

N. V. Bronina has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High-dose immunosuppressive therapy followed by haematopoietic stem cell transplantation as a method for the treatment of refractory forms of neuromyelitis optica spectrum disorder in children

    by N. N. Bronina, O. V. Bykova, G. O. Bronin, A. E. Kessel, G. Z. Seregin, K. I. Kirgizov, A. Yu. Polushin, T. T. Batysheva

    Neuromyelitis optica spectrum disorders (NMOSD) is a general term for immune-mediated diseases of the central nervous system whose phenotype includes affection of the optic nerve, brainstem encephalitis and myelitis. NMOSD is most commonly associated with class G antibodies against aquaporin-4 (aquaporin-4 immunoglobulin G, AQP4-IgG), less commonly with class G antibodies against the glycoprotein of myelin oligodendrocytes. There are also seronegative variants of NMOSD.The article describes our own experience in treating two boys with resistant NMOSD with AQP4-IgG positivity with high-dose immunosuppressive therapy (HIST) followed by haematopoietic stem cell transplantation (HSCT). In the first clinical observation, a case of resistant NMOSD in a 13-year-old boy is presented. Over the course of 6 months, the child’s neurological deficit progressed to 9.5 points on the Expanded Disability Status Scale (EDSS). After mobilization of peripheral stem cells (PSC), HIST was performed, followed by autologous HSCT (autoHSCT). During the 18-month follow-up, no NMOSD activity and the decrease in EDSS to 7.0 points were maintained. In the second clinical observation, the experience with the treatment of a child with resistant high-activity NMOSD is presented. A 10-year-old boy had two exacerbations within four months against the background of two lines of immunosuppressive therapy. PSCs were collected before auto-HSCT, but due to a further exacerbation and lack of clinical response to the mobilization dose of cyclophosphamide, it was decided to perform an allogeneic HSCT from a haploidentical donor. The follow-up period was 9 months. The EDSS score decreased from 6.5 to 3.5. AQP4-IgG was not detected in the blood of either patient. Both patients received satralizumab as part of consolidation therapy. No significant complications were observed after transplantation.Thus, HIST followed by HSCT can be considered a promising method for the treatment of resistant forms of NMOSD. The choice of HSCT type may depend on the severity of the patient’s somatic and neurological condition as well as the clinical response to immunosuppressive therapy.


  • Posterior reversible encephalopathy syndrome in children with hematological diseases

    by N.V. Bronina, I.O. Shchederkina, A.YU. Polushin, E.V. Seliverstova, Y.B. Skiba, K.I. Kirgizov, G.O. Bronin, I.A. Voznyuk

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка факторов риска (ФР) и тяжести течения синдрома задней обратимой энцефалопатии (PRES) у детей с заболеваниями системы крови. МАТЕРИАЛ И МЕТОДЫ Проанализированы случаи PRES у детей с заболеваниями системы крови на этапах полихимиотерапии (ПХТ) и после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). Оцениваемые ФР: артериальная гипертензия, терапия глюкокортикостероидами (ГКС), ПХТ/иммуносупрессивная терапия (ИСТ), инфекционный процесс, нарушение почечной функции. РЕЗУЛЬТАТЫ В анализ включено 35 случаев PRES у 32 детей (8 — после алло-ТГСК, 27 — на этапах ПХТ). В большинстве (94,3%) наблюдений PRES развился у пациентов с двумя ФР и более. Наиболее значимыми ФР были: повышение артериального давления (88,6%), проводимая ПХТ и ИСТ (82,8%), терапия ГКС (71,4%). Течение инфекционного процесса и снижение почечной функции играют меньшую роль в развитии PRES (31,4 и 14%). В дебюте PRES отмечались судороги (94,3%), нарушение уровня сознания (28,6%), головная боль, нарушение зрения и боли в животе (20%). В большинстве (91,4%) наблюдений — 2-я и 3-я степени тяжести по шкале оценки токсичности Common Terminology Criteria for Adverse Events (CTCAE 5.0). По данным магнитно-резонансной томографии (МРТ) головного мозга (ГМ), вазогенный отек выявлялся в теменных (88,6%), затылочных (74,3%), лобных (40%) долях и мозжечке (22,9%) чаще, чем цитотоксический отек (p=0,03). Цитотоксический отек был визуализирован в таламусе и базальных ганглиях (22,9%) чаще, чем в других отделах ГМ (pp<0,05).


  • IMMUNOTHERAPY WITH ANTI-GD2 MONOCLONAL ANTIBODIES IN HIGH-RISK NEUROBLASTOMA PATIENTS ON AN OUTPATIENT BASIS

    by M.V. Natrusova, G.O. Bronin, B.M. Kurmanov, V.V. Konstantinova, A.V. Lifshits, E.A. Zhuravel, N.V. Bronina, E.A. Burtsev, E.V. Kumirova, Moscow Morozov Children’s City Clinical Hospital

    Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Prior to the introduction of intensive multimodal therapy, overall survival (OS) in patients with high-risk NB was below 15%. The addition of immunotherapy with dinutuximab beta in post-consolidation to multimodal treatment can increase the 5-year event-free survival rate for patients with high-risk NB up to 56.6%, and the 5-year OS up to 73.2%. The purpose of the research was to study the efficacy and safety of dinutuximab beta therapy in high-risk NB patients. Materials and methods used: the study included 8 pediatric patients with high-risk NB who had been treated with dinutuximab beta immunotherapy during postconsolidation on the basis of the Morozov Children’s City Clinical Hospital (Moscow, Russia) in 2020 to 2022. In case a patient's vital parameters normalization coupled with the absence of the need for accompanying therapy for 24 hours in a hospital, the patient was then considered as a candidate for outpatient treatment with possible no need for admission in the hospital. Results: 6 patients (75%) completed the full course of therapy with dinutuximab beta. The course of immunotherapy was not completed in 2 patients due to further progression of the disease. The most common adverse events were recorded as follows: pain (100%), fever (100%), diarrhea (62.5%), edematous syndrome (37.5%), allergic reactions (25%), hematological toxicity (25%). The period of time to becoming the candidates for outpatient treatment was 10.38±2.56 days for the 1st cycle of therapy and 2.67±1.63 days for the last, 5th cycle of the immunotherapy. In 6 out of 8 cases described the immunotherapy with dinutuximab beta allowed maintaining the response to treatment achieved after the end of consolidation preventing further development of the disease. The overall good tolerance to the drug made it possible to carry out the immunotherapy on an outpatient basis using microinfusing pump. Conclusion: an adequate route of administration and accompanying treatment make dinutuximab beta toxicity profile sufficient for outpatient management of patients with high-risk NB.

  • IMMUNOTHERAPY WITH ANTI-GD2 MONOCLONAL ANTIBODIES IN HIGH-RISK NEUROBLASTOMA PATIENTS ON AN OUTPATIENT BASIS

    by M.V. Natrusova, G.O. Bronin, Moscow Morozov Children’s City Clinical Hospital, B.M. Kurmanov, V.V. Konstantinova, A.V. Lifshits, E.A. Zhuravel, N.V. Bronina, E.A. Burtsev, E.V. Kumirova

    Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Prior to the introduction of intensive multimodal therapy, overall survival (OS) in patients with high-risk NB was below 15%. The addition of immunotherapy with dinutuximab beta in post-consolidation to multimodal treatment can increase the 5-year event-free survival rate for patients with high-risk NB up to 56.6%, and the 5-year OS up to 73.2%. The purpose of the research was to study the efficacy and safety of dinutuximab beta therapy in high-risk NB patients. Materials and methods used: the study included 8 pediatric patients with high-risk NB who had been treated with dinutuximab beta immunotherapy during postconsolidation on the basis of the Morozov Children’s City Clinical Hospital (Moscow, Russia) in 2020 to 2022. In case a patient's vital parameters normalization coupled with the absence of the need for accompanying therapy for 24 hours in a hospital, the patient was then considered as a candidate for outpatient treatment with possible no need for admission in the hospital. Results: 6 patients (75%) completed the full course of therapy with dinutuximab beta. The course of immunotherapy was not completed in 2 patients due to further progression of the disease. The most common adverse events were recorded as follows: pain (100%), fever (100%), diarrhea (62.5%), edematous syndrome (37.5%), allergic reactions (25%), hematological toxicity (25%). The period of time to becoming the candidates for outpatient treatment was 10.38±2.56 days for the 1st cycle of therapy and 2.67±1.63 days for the last, 5th cycle of the immunotherapy. In 6 out of 8 cases described the immunotherapy with dinutuximab beta allowed maintaining the response to treatment achieved after the end of consolidation preventing further development of the disease. The overall good tolerance to the drug made it possible to carry out the immunotherapy on an outpatient basis using microinfusing pump. Conclusion: an adequate route of administration and accompanying treatment make dinutuximab beta toxicity profile sufficient for outpatient management of patients with high-risk NB.

  • Open Access

    Approaches to the treatment of a multisystem form of juvenile xanthogranuloma with central nervous system lesion

    by M. V. Natrusova, E. A. Burtsev, N. V. Bronina, D. S. Osipova, D. A. Evseev, E. V. Seliverstova, G. O. Bronin, M. A. Maschan, Е. V. Kumirova

    Relevance. Juvenile xanthogranuloma (JXG) is the most common form of non-Langerhans cell histiocytic disorder. Cutaneous forms of the disease spontaneously regress within a few years, while systemic forms of JXG require treatment and may pose a threat to the lives of patients. Due to the lack of unified approach to the treatment of multisystem forms of JXG, the question of effective therapy tactics remains unresolved. The most common approach is to use Langerhans cell histiocytosis (LCH) treatment regimens for JXG. With the understanding of the leading role of mutations in the MEK-ERK signaling pathway in the pathogenesis of JXG, targeted therapy, BRAF- and MEK-inhibitors, are increasingly being considered in the treatment of JXG.Clinical cases. We present two cases of multisystem JXG with central nervous system (CNS) lesions. The first patient with CNS and skin lesions was treated with chemotherapy, developed for the treatment of multisystem LCH, which allowed us to obtain an effect “active disease better” (AD better). The second JXG patient with brain, lungs, bones, and adrenal gland lesions, combined targeted therapy with BRAF- and MEKinhibitors, vemurafenib and cobimetinib, resulted in a “non active disease” (NAD) effect.Conclusion. Multisystem form of JXG with CNS involvement is a rare oncological disease, the therapy of which has not been developed. With the introduction of molecular genetic profiling technology, it became possible to obtain NAD effect using targeted therapy.


  • Open Access

    Anti-GAD encephalitis in a child with beta-thalassemia after allogeneic hematopoietic stem cell transplantation

    by N. V. Bronina, I. O. Schederkina, B. M. Kurmanov, E. A. Burtsev, M. V. Natrusova, G. O. Bronin

    Glutamic acid decarboxylase (GAD) is an intracellular enzyme expressed in brain neurons and insulin-secreting β-cells of the pancreas. Anti-GAD-anitibodies are associated with type 1 diabetes mellitus, limbic encephalitis, cerebellar ataxia, temporal autoimmune epilepsy, and rigid man syndrome. We present a rare clinical case of anti-GAD-anitibodies- associated immune encephalitis in a child with beta-thalassemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT).A 3-year-old boy diagnosed with beta-thalassemia underwent allo-HSCT from a 9/10 compatible unrelated donor. The macrophage activation syndrome occurred during the early post-transplantation period. The seizure with a focal onset happened on day +65. The cytotoxic edema in the region of the left hippocampus without signs of accumulation of a contrast agent was revealed at the magnetic resonance imaging of the brain. Pleocytosis, increase in protein levels, infection and antibodies to receptors and synaptic proteins of neurons were not detected at the analysis of cerebrospinal fluid. A positive titer to anti-GAD-anitibodies was detected in the blood – 315.82 IU/ml (the norm is up to 10 IU/ml). The child was treated with cyclophosphamide 750 mg/m2, rituximab 375 mg/m2, and tocilizumab 8 mg/kg. The cytotoxic edema in the left hippocampus regressed at the control magnetic resonance imaging on day +117.Infectious, immune and toxic agents can cause the damage of central nervous system in patients after allo-HSCT. The mechanism of immune damage to the central nervous system S in such patients is still being studied and may be different: expansion of autoreactive lymphocytes due to failure of T-cell regulation due to chemo- or immunosuppressive therapy, “passenger lymphocyte” syndrome, violation of T-cell regulation due to the course of infectious complications and acute graft versus host disease.In a series of diagnostic searches in patients with central nervous system lesions after allo-HSCT, it is necessary to include immune damage to the nervous system. Diagnosis of such conditions is a difficult task due to comorbidity and multicomponent accompanying therapy, including immunosuppressive therapy, administered to patients.


  • Open Access

    Stroke-like leukopathy in children with acute lymphoblastic leukemia

    by N. V. Natrusova, I. O. Shchederkina, E. V. Seliverstova, O. A. Tiganova, K. L. Kondratchik

    There are considerable variations in the reported incidence methotrexate-induced neurotoxicity in children with malignancies. The etiology of acute neurological deficit in pediatric patients with malignancies during polychemotherapy can be diverse: cerebrovascular disease (arterial ischemic stroke, intracranial hemorrhage, venous sinus thrombosis, or their combination), stroke-like migraine attacks after radiation therapy (SMART), posterior reversible encephalopathy syndrome (PRES), thrombotic microangiopathy, toxic leukoencephalopathy (include strokelike leukoencephalopathy). The tactics of a neurologist largely depends on the reasons that caused the neurological deficit. The doctor needs knowledge not only of the clinical picture and the characteristics of the course of the underlying disease, but also of possible complications arising both as a result of the disease itself and due to the therapy being carried out. Timely diagnosis and correct interpretation of emerging neurological events make it possible to determine rational accompanying therapy. The article presents case histories of children with acute lymphoblastic leukemias and acute neurological deficits, with an analysis of their possible causes.